Shingles Vaccine and Dementia Risk
Quick Facts
Can the shingles vaccine lower the risk of dementia?
Shingles, or herpes zoster, results from reactivation of the varicella-zoster virus, the same virus that causes chickenpox and then lies dormant in nerve cells. Researchers have long wondered whether viral reactivation and the inflammation it triggers might contribute to cognitive decline. Several population-level analyses have reported that vaccinated people go on to receive fewer dementia diagnoses than unvaccinated people, and a widely discussed study published in Nature used a so-called natural experiment in Wales to test the question more rigorously.
In that design, eligibility for the live-attenuated shingles vaccine depended on a person's birth date, so people born just before and just after the cutoff were similar in most respects except their chance of being offered the vaccine. Comparing the two groups reduces some of the confounding that undermines ordinary observational studies, such as healthier people being more likely to seek vaccination. The authors reported lower dementia diagnoses among those who were eligible. Even so, the approach cannot fully exclude every bias, and the results should be read as supportive rather than definitive.
Why might a vaccine against shingles affect the brain?
Several mechanisms have been proposed. Preventing shingles may reduce the number of times the virus reactivates and spreads along nerves, which could limit inflammation in or near the nervous system. Vaccination might also alter immune responses more broadly in ways that influence brain aging. Researchers are also studying whether non-specific immune effects of some vaccines play a role. These ideas remain hypotheses, and laboratory and clinical work is needed to separate real biological effects from statistical artifacts.
For patients, the practical message is straightforward. The CDC recommends the recombinant vaccine Shingrix, given as two doses two to six months apart, for adults aged 50 and older and for certain younger adults with weakened immune systems. Clinical trials showed it prevents shingles in more than 90 percent of recipients in the studied age groups, and it also lowers the risk of postherpetic neuralgia, a long-lasting nerve pain. Any potential cognitive benefit would be an added possibility, not the reason to vaccinate. Importantly, much of the dementia research involved the older live vaccine, so how the findings translate to Shingrix is still being studied.
Frequently Asked Questions
Current evidence does not justify vaccination for dementia prevention alone. The vaccine is recommended to prevent shingles and its complications, and any brain benefit would be a possible bonus that still needs confirmation in randomized trials.
The CDC recommends two doses of recombinant zoster vaccine for adults 50 and older, and for adults 19 and older who are or will be immunocompromised. Ask your clinician about timing, especially if you have had shingles before.
Common side effects include a sore arm, fatigue, muscle aches and fever for a day or two. Serious allergic reactions are rare. Discuss any previous vaccine reactions with your clinician.
References
- Centers for Disease Control and Prevention. Shingles (Herpes Zoster) Vaccination: Clinical Guidance for Shingrix.
- Nature. Natural experiment on herpes zoster vaccination and dementia diagnoses in Wales. 2025.
- Livingston G, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. 2024.